Table 5.

Mortality rate ratios (MRR) for trial participants after measles vaccine (MV) campaigns compared to before MV campaigns.

Trial Intervention	Recruitment period	Age group	MRR (MV/noMV)	Males	Females
II. Neonatal VAS vs placebo NBW 2-dose	2004–2007	0–11 months	0.63 (0.09–4.60)	0	1.37 (0.19–9.98)
IV. BCG-at-birth vs delayed BCG to LBW children	2004–2008	0–11 months	0.77 (0.24–2.46)	0	1.42 (0.44–4.56)
V. BCG-at-birth vs delayed BCG to LBW children	2008–2013	0–11 months	0	0	0
VI. OPV + BCG vs BCG-only	2008–2011	0–11 months	3.10 (0.95–10.1)	5.98 (1.81–19.7)	0
VII. VAS vs placebo with vaccines; 12 months follow-up	2007–2010	6–17 months	1.65 (0.77–3.54)	1.71 (0.66–4.44)	1.51 (0.45–5.03)
Combined result			1.24 (0.74–2.09)	1.34 (0.68–2.64)	1.14 (0.55–2.38)